STING1 and neoplasm: We discovered that the STINGa treatment induces type III IFNs in the TME and that tumor cell STING is required for robust type III IFN production, which in turn regulates type I IFN and other cytokines/chemokines for efficient anti-tumor responses to STING agonism as summarized in our proposed model (Fig. 6g).